Tail Gunner said:Dr. Howard said:I promised to follow up on heart/chest issues I had been having after being originally sick in March. Saw cardiologist today, he said that the infection may have done mild damage to my heart and that it is 'unfit' after so much bed rest, and lockdown inactivity. He figures it will heal on its own with time and exercise. I was able to handle the workload of a stress test with no problems, but the recovery time for my heart to return to a normal beating cycle is very long, which is where the problem is.
Dr. Howard, I am glad that you are better. There is breaking news today about COVID-19 causing blood clots. People are dying from these blood clots. It also explains all the heart attacks and the actor who lost his leg from poor circulation (who is also mentioned in this article). You should let your doctor know, so that he can take precautions.
Early data from China on a sample of 183 patients showed more than 70 percent of patients who died of covid-19 had small clots develop throughout their bloodstream. Although acute respiratory distress syndrome still appears to be the leading cause of death in covid-19 patients, blood complications are not far behind, said Behnood Bikdeli, a fourth-year fellow at Columbia University Irving Medical Center, who helped anchor a paper about the blood clots in the Journal of The American College of Cardiology. “My guess is it’s one of the top three causes of demise and deterioration in covid-19 patients,” he said.
An italian doctor said the same thing.
Spotlight on inflammation and blood clots in COVID-19 - complications of key concern
Giannini links the inflammation observed in COVID-19 patients, with the development of blood clots (thrombi) and potentially lethal cardiac or heart problems.
Giannini is not alone in his observations. Two separate groups of researchers from China have reported the results of their studies and they also suggest that inflammation plays a role in the development of heart injury in COVID-19 patients, which was strongly linked to a fatal outcome.
here has been some reluctance to use anti-inflammatory medications, including existing corticosteroids, because of concerns they may delay virus elimination and increase the risk of secondary infections. However, some anti-inflammatory agents are under investigation, including newer ones. Novel agents with anti-inflammatory properties that are being investigated for the treatment of COVID-19 include:
Baricitinib (Olumiant): This drug is a janus kinase (JAK) inhibitor, which is already used in the treatment of rheumatoid arthritis. This Eli Lilly drug was identified as a potential treatment for COVID-19 using BenevolentAI artificial intelligence platform.
Inhaled beta-interferon: An inhaled formulation of beta-interferon, assigned the code name SNG001, is also being investigated after showing promise in patients with asthma and chronic obstructive pulmonary disease (COPD) who also had lung infections, such as the flu.
Opaganib: Redhill’s experimental drug opaganib, a selective inhibitor of sphingosine kinase-2, has shown promise in the first two COVID-19 patients to receive the drug.
Ruxolitinib (Jakafi): Novartis’ ruxolitinib is another JAK inhibitor under investigation. It is already approved for the treatment of acute graft versus host disease (GVHD), myelofibrosis and polycythemia vera.
Tocilizumab (Actemra): Roche’s anti-interleukin-6 (IL-6) receptor therapeutic, tocilizumab, is another agent of interest. It is already approved for the treatment of rheumatoid arthritis and other conditions, including severe or life-threatening cytokine release syndrome following chimeric antigen receptor T cell treatment.